News
Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...
Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback